Leap Therapeutics, Inc. (5MC.F)
| Previous close | 2.6200 |
| Open | 2.4800 |
| Bid | 2.6200 x N/A |
| Ask | 2.8000 x N/A |
| Day's range | 2.4800 - 2.4800 |
| 52-week range | 1.0300 - 8.5000 |
| Volume | |
| Avg. volume | 65 |
| Market cap | 94.896M |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.6900 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress
Significant Reduction in Net Loss and Strategic Clinical Advancements
PR NewswireLeap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.
- PR Newswire
Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise
